These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 28468742)

  • 21. A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group.
    Pignata S; Scambia G; Pisano C; Breda E; Di Maio M; Greggi S; Ferrandina G; Lorusso D; Zagonel V; Febbraro A; Riva N; De Rosa V; Gallo C; Perrone F;
    Br J Cancer; 2007 Jun; 96(11):1639-43. PubMed ID: 17486128
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recall inflammatory skin reaction after use of pegylated liposomal doxorubicin in site of previous drug extravasation.
    Saini A; Berruti A; Sperone P; Bitossi R; Tampellini M; Dogliotti L; Gorzegno G
    Lancet Oncol; 2006 Feb; 7(2):186-7. PubMed ID: 16455484
    [No Abstract]   [Full Text] [Related]  

  • 23. Pegylated liposomal doxorubicin-induced palmar-plantar erythrodysestesia in multiple uncommon sites.
    Corazza M; Minghetti S; Zauli S; Ricci M; Borghi A; Virgili A
    Eur J Dermatol; 2011; 21(3):433-4. PubMed ID: 21515437
    [No Abstract]   [Full Text] [Related]  

  • 24. Elevated body mass index does not increase the risk of palmar-plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin.
    Gordinier ME; Dizon DS; Fleming EL; Weitzen S; Schwartz J; Parker LP; Granai CO
    Gynecol Oncol; 2006 Oct; 103(1):72-4. PubMed ID: 16494932
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pegylated liposomal doxorubicin and carboplatin in late-relapsing ovarian cancer: a GINECO group phase II trial.
    Weber B; Lortholary A; Mayer F; Bourgeois H; Orfeuvre H; Combe M; Platini C; Cretin J; Fric D; Paraiso D; Pujade-Lauraine E
    Anticancer Res; 2009 Oct; 29(10):4195-200. PubMed ID: 19846972
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemotherapy-induced acral erythema.
    Vargas-Díez E; Abajo P; Fraga J; Fernández-Herrera J; García-Díez A
    Acta Derm Venereol; 1999 Mar; 79(2):173-5. PubMed ID: 10228652
    [No Abstract]   [Full Text] [Related]  

  • 27. Efficacy of Pegylated Liposomal Doxorubicin in Low-Grade Serous Ovarian Carcinoma.
    Rose PG; Radeva M; Michener CM; Link N; Adbul-Karim F
    Int J Gynecol Cancer; 2017 Jun; 27(5):907-911. PubMed ID: 28498259
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.
    Strauss HG; Hemsen A; Karbe I; Lautenschläger C; Persing M; Thomssen C
    Anticancer Drugs; 2008 Jun; 19(5):541-5. PubMed ID: 18418221
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delayed neoplastic and renal complications in women receiving long-term chemotherapy for recurrent ovarian cancer.
    Muggia F; Cannon T; Safra T; Curtin J
    J Natl Cancer Inst; 2011 Jan; 103(2):160-1. PubMed ID: 21115880
    [No Abstract]   [Full Text] [Related]  

  • 30. Peculiar acral erythema secondary to high-dose chemotherapy for acute myelogenous leukemia.
    Burgdorf WH; Gilmore WA; Ganick RG
    Ann Intern Med; 1982 Jul; 97(1):61-2. PubMed ID: 7046555
    [No Abstract]   [Full Text] [Related]  

  • 31. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
    Pujade-Lauraine E; Wagner U; Aavall-Lundqvist E; Gebski V; Heywood M; Vasey PA; Volgger B; Vergote I; Pignata S; Ferrero A; Sehouli J; Lortholary A; Kristensen G; Jackisch C; Joly F; Brown C; Le Fur N; du Bois A
    J Clin Oncol; 2010 Jul; 28(20):3323-9. PubMed ID: 20498395
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial.
    Pignata S; Scambia G; Savarese A; Breda E; Sorio R; Pisano C; Lorusso D; Cognetti F; Vernaglia Lombardi A; Gebbia V; Scollo P; Morabito A; Signoriello G; Perrone F
    Oncology; 2009; 76(1):49-54. PubMed ID: 19039248
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients.
    von Gruenigen V; Frasure H; Fusco N; DeBernardo R; Eldermire E; Eaton S; Waggoner S
    Cancer; 2010 Oct; 116(20):4735-43. PubMed ID: 20629022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer.
    Vergote I; Finkler N; del Campo J; Lohr A; Hunter J; Matei D; Kavanagh J; Vermorken JB; Meng L; Jones M; Brown G; Kaye S;
    Eur J Cancer; 2009 Sep; 45(13):2324-32. PubMed ID: 19515553
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cancer chemotherapy and acral erythema.
    Ann Intern Med; 1982 Nov; 97(5):783-4. PubMed ID: 7137746
    [No Abstract]   [Full Text] [Related]  

  • 36. Distal phalange necrosis: a severe manifestation of palmar plantar erythrodysesthesia.
    Palaia I; Angioli R; Bellati F; Basile S; Rabitti C; Panici PB
    Am J Obstet Gynecol; 2006 Oct; 195(4):e1-2. PubMed ID: 16875651
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acral erythema induced by chemotherapy with cisplatin.
    Vakalis D; Ioannides D; Lazaridou E; Mattheou-Vakali G; Teknetzis A
    Br J Dermatol; 1998 Oct; 139(4):750-1. PubMed ID: 9892931
    [No Abstract]   [Full Text] [Related]  

  • 38. Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters.
    Ajgal Z; Chapuis N; Emile G; Cessot A; Tigaud JM; Huillard O; Boudou-Rouquette P; Fontenay M; Goldwasser F; Alexandre J
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1033-9. PubMed ID: 26420236
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
    Sehouli J; Camara O; Schmidt M; Mahner S; Seipelt G; Otremba B; Schmalfeldt B; Tesch H; Lorenz-Schlüter C; Oskay-Ozcelik G;
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):585-91. PubMed ID: 19156414
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eccrine squamous syringometaplasia secondary to pegylated liposomal doxorubicin.
    Garcia-Navarro X; Puig L; Fernández-Figueras MT; Alomar A
    Arch Dermatol; 2008 Oct; 144(10):1402-3. PubMed ID: 18936417
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.